Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNovartis Pharmaceuticals

About this trial

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases.

The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.

Eligibility criteria

Qualifiers

Patients treated with OAV-101 with a genetically confirmed diagnosis of SMA regardless of the date of diagnosis.

Appropriate consent/assent has been obtained for participation in the registry

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Prospective observational registry
  • Zolgensma

Treatment groups

700 Participants
are divided into 1 treatment group

Sponsors and collaborators